Unveiling New Strategies to Enhance Immune Checkpoint Inhibitor Drugs
Cancer cells have a cunning strategy to evade the immune system's watchful eye. They exploit natural immune checkpoints, which are designed to prevent the body from attacking its own cells, by producing proteins that bind to checkpoint receptors on T cells. This binding effectively halts the T cells' ability to recognize and target the tumor. To counter this, immune checkpoint inhibitor (ICI) drugs are used to block this interaction, allowing T cells to once again identify and combat tumor cells.
ICI drugs have shown remarkable success, particularly with ipilimumab (Yervoy) from Bristol-Myers Squibb, which was approved by the FDA in 2011 for treating unresectable or metastatic melanoma. This has led to significant improvements in long-term survival for many patients. However, the response rate to ICIs remains low, with only about 20 to 40 percent of patients across all cancer types benefiting from these treatments. This highlights the urgent need for innovative strategies to make ICIs more effective for a broader range of patients.
Two recent studies offer fresh insights into why some patients don't respond to ICIs and how we might overcome this challenge.
In a groundbreaking study published in Science Advances, researchers led by Yi Zheng at Cincinnati Children's Hospital discovered a mutation that confers resistance to ICIs targeting the PD-1 checkpoint receptor. Specifically, the team found that a mutation in the RAC1 gene, known as A159V, leads to the development of an immunosuppressive tumor microenvironment. This environment hinders the effectiveness of ICI drugs in mice by activating mTORC1 signaling. This signaling pathway increases the tumor's glucose consumption, suppresses chemokine production, and decreases IFNGR1 expression, all of which prevent the immune system from effectively attacking the tumor.
The researchers also demonstrated that administering rapamycin, an FDA-approved drug that inhibits mTORC1 signaling, successfully sensitized tumor cells to the ICI drug, thereby overcoming the resistance caused by the genetic mutation. This discovery suggests that further research could lead to personalized treatment strategies for patients with this specific gene mutation, potentially combining ICI therapy with other treatments.
A second paper, published in the Journal for ImmunoTherapy of Cancer, introduces a novel approach to developing second-generation therapies targeting the PD-L1 checkpoint protein. Tumor cells express PD-L1 on their surface, which binds to PD-1 on T cells, sending an 'off' signal that suppresses the immune response. Typically, PD-L1 is recycled back to the tumor cell surface, maintaining the immunosuppressive effect.
Haidong Dong's lab at the Mayo Clinic developed an anti-PD-L1 antibody, H1A, using in vivo humanized PD-1/PD-L1 mouse tumor models. This antibody demonstrated superior tumor control compared to standard ICI drugs by boosting the activity of myeloid cells. Enhanced myeloid cell activity promoted PD-L1 degradation on tumor cells, rather than its recycling, leading to improved immune system recognition and attack of the tumor.
Michelle Hsu, a biomedical scientist at the Mayo Clinic and lead author of the study, emphasized the potential of H1A, stating that it can completely remove PD-L1, thereby activating more myeloid cells. The team is now planning a Phase 1 clinical trial with H1A, which could pave the way for more effective ICI drugs and underscore the importance of basic research in identifying innovative solutions to improve treatment outcomes for a wider range of patients.
